MeSH D012878 - skin neoplasms
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D012878:Â
Skin neoplasms
D012626:Sebaceous gland neoplasms
0 Companies
0 Drugs
Success rate
D013544:Sweat gland neoplasms
0 Companies
0 Drugs
Success rate
D034701:Cutaneous mastocytosis
0 Companies
0 Drugs
Success rate
D000096142:Cutaneous malignant melanoma
0 Companies
0 Drugs
Success rate
D008545:Melanoma
D049309:Acanthoma
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Genentech | Vismodegib | Erivedge | 2025-09-02 | 2012-01-30 |  |  |
| Horizon Therapeutics Public | Interferon gamma-1b | Actimmune |  | 1999-02-25 | $122.816 M | Q3/22-Q2/23 |
| Merck & Co | Interferon alfa-2b | Intron A |  | 1986-06-04 |  |  |
| Interferon alfa-2b | IntronA |  | 2000-03-09 |  |  | |
| Interferon alfa-2b | Viraferon |  | 2000-03-09 |  |  | |
| Organon | Alendronate, Cholecalciferol | Fosamax D |  | 2005-04-07 |  |  |
| Pharma& | Peginterferon alfa-2a | Pegasys |  | 2002-10-16 |  |  |
| Roche | Vismodegib | Erivedge |  | 2013-07-12 | $303.263 M | Q4/22-Q3/23 |
| Ribavirin, Peginterferon alfa-2a | Pegasys Copegus |  | 2004-06-04 |  |  | |
| Interferon alfa-2a | Roferon-A |  | 1986-06-04 |  |  | |
| Sandoz | Folic acid, Dexpanthenol, Ascorbic acid, Cyanocobalamin, Vitamin a, Alpha-tocopherol, Biotin, Cholecalciferol, Niacinamide, Pyridoxine, Riboflavin, Thiamine, Tocopherol | Infuvite |  | 2000-05-18 |  |  |
| Sun Pharmaceutical Industries | Sonidegib | Odomzo | 2029-07-24 | 2015-07-24 |  |  |
Clinical Trials
Historical Success Rate
Phase 1
53%16/30
Phase 2
8%6/71
Phase 3
50%12/24
Approved: 8Overall Success rate: 2%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use